Daratumumab,Carfilzomib,Lenalidomide,Dexamethasone
Janssen,Amgen
#ims2022 high-risk mm presenters discussed risk stratification, prognostic factors, and potential implications of small subclones. results of phase 2 trials w/ therapeutics daratumuab carflizomib lenalidomide, and dexamethasone in high-risk/newly diagnosed mm pts are also shown. 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.